title: Technology evaluation: cT84.66, City of Hope.
abstract: Chimeric T84.66 (cT84.66) is a high affinity anti-carcinoembryonic antigen (CEA) immunoglobulin G1, that is being developed by City of Hope for the potential treatment of CEA-expressing malignancies.
authors.affiliation: Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA. rblumenthal@gscancer.org
authors.forename: Rosalyn D
authors.initials: RD
authors.lastname: Blumenthal
mesh_terms: D001943:Breast Neoplasms / Q000628:therapy; D002272:Carcinoembryonic Antigen / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000628:therapy; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D016499:Radioimmunotherapy / Q000379:methods; D013329:Structure-Activity Relationship; D015021:Yttrium Radioisotopes
chemical_list: D002272:Carcinoembryonic Antigen; D007074:Immunoglobulin G; D015021:Yttrium Radioisotopes